Page 16 - Read Online
P. 16

Page 12 of 14       Haydu et al. J Cancer Metastasis Treat 2021;7:36  https://dx.doi.org/10.20517/2394-4722.2021.39

               Financial support and sponsorship
               None.


               Conflict of interest
               Abramson JS reports consulting for Bristol-Myers Squibb, Celgene, Gilead, Kite Pharma, Novartis and
               Allogene. Haydu JE reports no disclosures.

               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               ©The Author(s) 2021.

               REFERENCES
               1.       Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7-33.  DOI  PubMed
               2.       Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
                   Blood 2016;127:2375-90.  DOI  PubMed  PMC
               3.       Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international
                   SCHOLAR-1 study. Blood 2017;130:1800-8.  DOI  PubMed  PMC
               4.       Epperla N, Hamadani M, Cashen AF, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell
                   lymphoma-a "real world" study. Hematol Oncol 2017;35:528-35.  DOI  PubMed
               5.       Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma
                   (MCL) who discontinued ibrutinib. Br J Haematol 2018;183:578-87.  DOI  PubMed
               6.       Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016;127:1559-63.
                   DOI  PubMed
               7.       Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin,
                   vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol
                   2015;33:2516-22.  DOI  PubMed  PMC
               8.       Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood
                   2015;125:2062-7.  DOI  PubMed  PMC
               9.       Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell
                   lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396:839-52.  DOI  PubMed
               10.      Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J
                   Med 2017;377:2531-44.  DOI  PubMed  PMC
               11.      Schuster SJ, Bishop MR, Tam CS, et al; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell
                   lymphoma. N Engl J Med 2019;380:45-56.  DOI  PubMed
               12.      Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med
                   2020;382:1331-42.  DOI  PubMed  PMC
               13.      Jacobson C, Chavez JC, Sehgal AR, et al. Primary analysis of Zuma-5: a phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in
                   patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Blood 2020;136:40-1.
               14.      Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents
                   induction of anergy in T-cell clones. Nature 1992;356:607-9.  DOI  PubMed
               15.      Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T
                   cells in lymphoma patients. J Clin Invest 2011;121:1822-6.  DOI  PubMed  PMC
               16.      Salter AI, Ivey RG, Kennedy JJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and
                   quantitative differences that affect cell function. Sci Signal 2018;11:1-17.  DOI  PubMed  PMC
               17.      Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-
                   specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016;8:1-12.  DOI  PubMed  PMC
               18.      Locke FL, Ghobadi A, Jacobson CA, et al. Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-
                   cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20:31-42.  DOI  PubMed  PMC
               19.      Ramsborg CG, Guptill P, Weber C, et al. JCAR017 is a defined composition CAR T cell product with product and process controls
                   that deliver precise doses of CD4 and CD8 CAR T cell to patients with NHL. Blood 2017;130:4471.  DOI
               20.      Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+
                   subsets confer superior antitumor reactivity in vivo. Leukemia 2016;30:492-500.  DOI  PubMed  PMC
   11   12   13   14   15   16   17   18   19   20   21